Related Experiment Video
Updated: Jun 7, 2025

Identification of MyoD Interactome Using Tandem Affinity Purification Coupled to Mass Spectrometry
Published on: May 17, 2016
Myc 9aaTAD activation domain binds to mediator of transcription with superior high affinity
Andrea Knight1,2,3, Josef Houser4,5,6, Tomas Otasevic7
1School of Life Science, Faculty of Science and Engineering, Anglia Ruskin University, East Road, Cambridge, CB1 1PT, UK. andrea.knight@aru.ac.uk.
Abstract:
The overexpression of MYC genes is frequently found in many human cancers, including adult and pediatric malignant brain tumors. Targeting MYC genes continues to be challenging due to their undruggable nature. Using our prediction algorithm, the nine-amino-acid activation domain (9aaTAD) has been identified in all four Yamanaka factors, including c-Myc. The predicted activation function was experimentally demonstrated for all these short peptides in transactivation assay. We generated a set of c-Myc constructs (1-108, 69-108 and 98-108) in the N-terminal regions and tested their ability to initiate transcription in one hybrid assay. The presence and absence of 9aaTAD (region 100-108) in the constructs strongly correlated with their activation functions (5-, 3- and 67-times respectively). Surprisingly, we observed co-activation function of the myc region 69-103, called here acetyl-TAD, previously described by Faiola et al. (Mol Cell Biol 25:10220-10234, 2005) and characterized in this study as a new domain collaborating with the 9aaTAD. We discovered strong interactions on a nanomolar scale between the Myc-9aaTAD activation domains and the KIX domain of CBP coactivator. We showed conservation of the 9aaTADs in the MYC family. In summary for the c-Myc oncogene, the acetyl-TAD and the 9aaTAD domains jointly mediated activation function. The c-Myc protein is largely intrinsically disordered and therefore difficult to target with small-molecule inhibitors. For the c-Myc driven tumors, the strong c-Myc interaction with the KIX domain represents a promising druggable target.
Insights
Targeting MYC genes in cancer is difficult. Researchers identified two key domains, acetyl-TAD and 9aaTAD, in c-Myc that work together for activation, offering a potential new therapeutic target.
Area of Science:
- Oncology
- Molecular Biology
- Biochemistry
Background:
- MYC gene overexpression is common in human cancers, including brain tumors.
- MYC proteins are intrinsically disordered, making them challenging to target with drugs.
- The nine-amino-acid activation domain (9aaTAD) is a key functional region in MYC proteins.
Purpose of the Study:
- To identify and characterize functional domains within the c-Myc oncogene.
- To investigate the interaction between c-Myc domains and coactivators.
- To explore novel therapeutic strategies for MYC-driven cancers.
Main Methods:
- Utilized a prediction algorithm to identify the 9aaTAD in c-Myc.
- Performed transactivation assays to test the function of short c-Myc peptides.
- Generated and tested c-Myc constructs with and without the 9aaTAD in a one-hybrid assay.
- Characterized the acetyl-TAD domain and its collaboration with 9aaTAD.
- Investigated interactions between Myc activation domains and the CBP coactivator's KIX domain using biophysical methods.
Main Results:
- The 9aaTAD (region 100-108) was confirmed as a critical activation domain in c-Myc.
- A novel collaborating domain, acetyl-TAD (region 69-103), was identified and characterized.
- The presence of 9aaTAD strongly correlated with transcriptional activation.
- Strong nanomolar interactions were observed between Myc-9aaTAD and the CBP KIX domain.
- 9aaTADs were found to be conserved across the MYC family.
Conclusions:
- The c-Myc oncogene's activation function is jointly mediated by the acetyl-TAD and 9aaTAD domains.
- The interaction between c-Myc and the CBP KIX domain presents a druggable target for c-Myc-driven tumors.
- Understanding these domains offers new avenues for developing targeted cancer therapies.
Related Concept Videos
Master Transcription Regulators
Eukaryotic Transcription Activators
The binding domains are capable of recognizing and interacting with regulatory sequences on the DNA. These...
Co-activators and Co-repressors
RNA Polymerase II Accessory Proteins
Cooperative Binding of Transcription Regulators
Eukaryotic Transcription Inhibitors
Eukaryotic transcription inhibitors usually contain two distinct domains, a...

